US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1830 Views
-
Last post by frodo
-
- 0 Replies
- 1175 Views
-
Last post by NHE
-
- 0 Replies
- 1655 Views
-
Last post by frodo
-
- 0 Replies
- 1187 Views
-
Last post by frodo
-
- 1 Replies
- 1637 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 2221 Views
-
Last post by NHE
-
- 0 Replies
- 1033 Views
-
Last post by frodo
-
- 1 Replies
- 1354 Views
-
Last post by NHE